RNF168-mediated localization of BARD1 recruits the BRCA1-PALB2 complex to DNA damage

por John J. Krais, Yifan Wang, Pooja Patel, Jayati Basu, Andrea J. Bernhardy, Neil Johnson
Publicado 2021

BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance

por Yifan Wang, Andrea J. Bernhardy, Joseph Nacson, John J. Krais, Yin-Fei Tan, Emmanuelle Nicolas, Marc R. Radke, Elizabeth Handorf, Alba Llop-Guevara, Judith Balmaña, Elizabeth M. Swisher, Violeta Serra, Suraj Peri, Neil Johnson
Publicado 2019

Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models

por Hyoung Kim, Haineng Xu, Erin George, Dorothy Hallberg, Sushil Kumar, Veena Jagannathan, Sergey Medvedev, Yasuto Kinose, Kyle Devins, Priyanka Verma, Kevin Ly, Yifan Wang, Roger A. Greenberg, Lauren Schwartz, Neil Johnson, Robert B. Scharpf, Gordon B. Mills, Rugang Zhang, Victor E. Velculescu, Eric J. Brown, Fiona Simpkins
Publicado 2020

Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma

por Olga Kondrashova, Monique Topp, Ksenija Nesic, Elizabeth Lieschke, Gwo-Yaw Ho, Maria I. Harrell, Giada V. Zapparoli, Alison Hadley, Robert Holian, Emma Boehm, Valerie Heong, Elaine Sanij, Richard B. Pearson, John J. Krais, Neil Johnson, Orla McNally, Sumitra Ananda, Kathryn Alsop, Karla J. Hutt, Scott H. Kaufmann, Kevin K. Lin, Thomas C. Harding, Nadia Traficante, Australian Ovarian Cancer Study (AOCS), Anna deFazio, Iain A. McNeish, David D. Bowtell, Elizabeth M. Swisher, Alexander Dobrovic, Matthew J. Wakefield, Clare L. Scott
Publicado 2018